ABBOTINDIABSEAbbott India LtdMediumNeutral
Announced Wed, 16 Apr · 09:30 IST

Appointment of Senior Management Personnel

Management Changes View source PDF

ABBOTINDIA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Abbott India has appointed Ms. Anushree Kunhambu as Associate Director – New Product Introduction and Therapy Area Strategy, effective August 1, 2025. She will be part of the company's Senior Management team. The appointment was recommended by the Nomination and Remuneration Committee and approved by the Board of Directors. Anushree has over a decade of experience in healthcare strategy, licensing, and business development, and has been with Abbott since April 2021, most recently as Head – Strategy & Portfolio, EPD India. She has previously worked at GLG (Life Sciences) and Cipla's Corporate Strategy team, and holds a BTech in Biotechnology from SRM University along with a Young India Fellowship from Ashoka University. She is not related to any existing Directors, KMP, or Senior Management of the company.

Likely market impact

This is a routine senior management appointment with no change at the board or KMP level. Shareholders are unlikely to see any immediate material impact on the stock price, though the addition of an experienced strategy leader may support the company's new product pipeline and therapy area expansion efforts over time.